News Releases

-- Conference Call Scheduled for 4:30 p.m. ET -

- High Percentage of Women Converting to Phexxi from Hormonal Birth Control -

-- Company Would Receive up to an Additional $50 Million Upon Exercise of Accompanying Short-Term Warrants --

-- Qualitative Research found Product Satisfaction and the Impact of EVO100 on Sexual Satisfaction were Important and Meaningful to Assess and would be Tied to Product Use --

- Potential for Expedited NDA Review of EVO100 by FDA -

-- Net Revenues Increased 550% Compared to 2020 Fourth Quarter --

-- Conference Call Scheduled for 4:30 p.m. ET --

Posters Focus on Perfect-Use Efficacy Data and Sexual Satisfaction and Function Among Women in the Phase 3 AMPOWER Trial

- Over 2,400 Phexxi units dispensed in February 2021, up 30% from prior month -

-- Phexxi® (lactic acid, citric acid and potassium bitartrate) vaginal gel prescriptions growing month over month, catalyzed by "Get Phexxi" Direct-to-Consumer (DTC) Campaign launched February 14th --

-- Conference Call Scheduled for 4:30 p.m. ET --

Marketing campaign includes the brand's first-ever commercial spot introducing women to a birth control that puts them in control of their body, their sex life, and their pregnancy prevention.

Collaboration will provide resources about Phexxi® contraceptive vaginal gel to oncologists, pharmacists and associated healthcare providers

Evofem honored amongst best companies globally for outstanding innovation with first-in-class non-hormonal prescription contraceptive vaginal gel, Phexxi®

Approximately 25 Million Adult Women Covered by Medicaid

High Level of Interest from Clinical Sites Seeking to Participate in EVOGUARD Trial

Launched Phexxi™ (lactic acid, citric acid, potassium bitartrate) in U.S. for Hormone-free Contraception

-- Conference Call Scheduled for 5:00 p.m. ET --

- Live moderated video webcast discussion with members of Evofem management and Key Opinion Leader Patty Cason, RN, MS, FNP-BC, on Thursday, October 29th at 2:00 p.m. ET -

- Company plans to initiate Phase 3 STI trial by the end of 2020 -

- A First-in-Class Vaginal pH Modulator Designed for Use "In-the-Moment" -

- Advancing Precommercial Activities in Preparation for Phexxi™ Commercial Launch in September 2020 -

-- Conference Call Scheduled for 11:00 a.m. EDT --

- On-Track for September Launch of Phexxi™, the First FDA-Approved, Non-Hormonal, On-Demand Prescription Contraceptive Gel -

- A New Class of Female-Controlled Birth Control for Use In-The-Moment -